drugset / Trial / NCT02772159

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT02772159

Phase 1 Completed 9 enrolled Mylan Inc. Theravance Biopharma · collab
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of an investigational medication used to treat chronic obstructive pulmonary disease (COPD). The study drug will be tested in 6 healthy normal males. Dosing will include a single dose of study drug administered via an IV Infusion and an Oral Dose. There will be a 28 day washout period between each of the 2 dosing routes.

Timeline

Start
2015-06
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Revefenacin Small molecule 20 ug Intravenous
Subject Revefenacin Small molecule 200 ug Intravenous